IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC maintenance in patients with extranodal marginal zone lymphoma (MZL) who received frontline treatment with chlorambucil plus rituximab. Study treatm...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Anastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, Pierre Feugier, Monica Tani, Hervé Ghesquières, Gerardo Musuraca, Francesca Gaia Rossi, Francesco Merli, Romain Guièze, Emmanuel Gyan, Guido Gini, Dario Marino, Remy Gressin, Franck Morschhauser, Federica Cavallo, Francesca Palombi, Annarita Conconi, Benoît Tessoulin, Hervé Tilly, Manuela Zanni, Maria Giuseppina Cabras, Enrico Capochiani, Catello Califano, Melania Celli, Alessandro Pulsoni, Francesco Angrilli, Ubaldo Occhini, René-Olivier Casasnovas, Guillaume Cartron, Liliana Devizzi, Corinne Haioun, Anna Marina Liberati, Roch Houot, Michele Merli, Giuseppe Pietrantuono, Francesca Re, Michele Spina, Francesco Landi, Franco Cavalli, Francesco Bertoni, Davide Rossi, Nicoletta Ielmini, Elena Borgo, Stefano Luminari, Emanuele Zucca, Catherine Thieblemont
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Ferrata Storti Foundation 2024-02-01
Serie:	Haematologica
Accesso online:	https://haematologica.org/article/view/11459
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!